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Cirrhosis has a long natural history with considerable symp-
tomatic impacts, particularly in advancing disease. Measur-
ing health related quality of life (HRQOL) in liver disease
provides detail about the nature and extent of its effects
on individuals. Understanding the drivers of impaired
HRQOL can help identify targets for improvement through
new treatments or health systems service delivery. Evalua-
tion of novel therapies which target symptomatic improve-
ment, should be done with suitable outcome measures,
including HRQOL assessment. In this article, we provide an
overview of HRQOL in advanced liver disease for the
clinician. A clear description of the important HRQOL tools
is given alongside a discussion of the factors, which are
known to contribute to impaired HRQOL in advanced liver
disease.
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BMI, body mass index.Introduction and clinical context
The burden of liver disease is increasing, largely due to the com-
bined impacts of alcohol related liver disease (ARLD) [1], non-
alcoholic fatty liver disease (NAFLD) [2] and viral hepatitis
[3,4]. Liver disease is often sub-clinical until more advanced dis-
ease is established, resulting in an increasing incidence of cirrho-
sis in many countries [5]. Medical approaches to cirrhosis, such
as screening for hepatocellular carcinoma (HCC) and variceal sur-
veillance, often focus on risk reduction. While these strategies,
targeted to clinical factors, are clearly important, they do not
consider patient factors such as health related quality of life
(HRQOL). Measuring HRQOL can quantify the impact of a disease
and its treatment on the individual and is increasingly recogni-
sed as an important outcome in chronic diseases such as
cirrhosis.
Compensated cirrhosis is associated with a median sur-
vival of 12 years [6] meaning that even patients who go onto
liver transplantation will have lived for considerable periods
of time with advanced disease. Evaluation of treatments for
cirrhosis usually consider clinical end points such as mortal-
ity rates, biochemistry results or the incidence of complica-
tions, but these do not consider patients’ values. Measuring
HRQOL can reﬂect the emotional, physical and lifestyle
implications of medical conditions and treatments, which
are typically more important to patients than traditional
outcomes [7].
An understanding of the factors which drive impaired
HRQOL in advanced liver disease should allow identiﬁcation
of targets for novel therapies. Increased awareness of
HRQOL should enable provision of services with a balance
between clinical and patient factors. Many treatments for
advanced liver disease aim to alleviate speciﬁc symptoms
rather than improving long term outcomes; such treatments
are therefore best evaluated with a robust assessment of
HRQOL.14 vol. 61 j 1158–1165
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• Health Related Quality of Life (HRQOL) measures 
reflect the emotional, physical and lifestyle implications 
of a disease and are increasingly recognised as 
important in chronic diseases such as cirrhosis where 
many treatments are life-enhancing rather than life-
prolonging
• Studies of HRQOL in liver disease usually combine a 
generic measure (e.g., SF-36 or SIP) with a disease-
specific measure (e.g., LDQOL or CLDQ)
• HRQOL is more significantly impaired in patients with 
cirrhosis than in both healthy controls and in patients 
with non-cirrhotic chronic liver disease. Impairment 
increases with increasing severity of cirrhosis (MELD 
score or Child-Pugh score)
• Clinical factors, which contribute to impaired HRQOL, 
include the presence of ascites, hepatic encephalopathy 
or hyponatraemia
• There is some evidence to support the reversibility of 
HRQOL impairment suggesting that targeting specific 
symptoms is likely to be the route to overall HRQOL 
improvementMeasuring health-related quality of life
There are a variety of methods available for measuring HRQOL,
which can reﬂect both objective and subjective aspects. Objective
constructs can measure an individual’s ability to carry out spe-
ciﬁc tasks or activities, while subjective measures relate to the
perceived impact of health status on wellbeing [8]. These two
approaches are complimentary: while objective measures tend
to be easier to analyse, subjective measures relate to the patient
experience more closely.
Generic measurement scales provide an overview of HRQOL,
usually taking into account physical, mental and social aspects
of the health status. An advantage of generic scales is that they
allow the relative impact of different diseases to be studied,
which can be useful to health policy makers. In addition, exten-
sive normative data allow comparisons with the general popula-
tion. The main disadvantage is a lack of sensitivity to clinically
important changes. For this reason, generic scales are often com-
bined with disease-speciﬁc scales, which measure clinical and
social factors directly relevant to the condition being studied.
Disease-speciﬁc scales should show how disease severity, clinical
outcomes and the effects of treatment affect HRQOL. Domain-
speciﬁc scales, which focus on one speciﬁc area of interest, such
as sleep or fatigue, are sometimes also added. Clearly, the addi-
tional detail, which can be achieved using more tools, must be
balanced against participant burden [9].
Questionnaire-based tools frequently use categorical Likert
scales with a series of ordered responses (e.g., never, rarely,
sometimes, most of the time, always), although dichotomous cat-
egorical questions (e.g., yes/no) or visual analogue scales (VAS)
are sometimes used. Measurements of HRQOL can be patient-
derived or derived from non-patient populations, such as
physicians. While there are theoretical advantages from using
non-patient populations, such as reduced subjectivity [10], it isJournal of Hepatology 2014generally recognised that patient-derived HRQOL measurements
are more valuable [9].
Health utilities are subtly different from HRQOL indices and
are used to assign a single value, which represents a preference
for a speciﬁc state of health [11]. In practice, utility scores fall
between 0 and 1, where 0 corresponds to death and 1 to perfect
health, although in some cases a negative score can be assigned
to health states considered to be worse than death (e.g., uncon-
sciousness) [12]. Utility values are used to calculate quality
adjusted life years (QALYs), which combine length of life with
quality of life such that a year of full health is equal to 1 QALY
[11]. QALYs allow comparisons to be made between different
conditions and are widely used in health technology assessments.
There are various different techniques to derive utility values,
described elsewhere [13,14].HRQOL tools used in studies of chronic liver disease
The wide variety of tools can make it difﬁcult to assimilate the
literature on HRQOL, not least because of the variation in
domains measured and scales used. The generic and disease-spe-
ciﬁc tools most commonly used in studies of HRQOL in liver dis-
ease are summarised in Tables 1 and 2 respectively and a brief
description is given below to help contextualise the subsequent
literature review.
SF-36 is the most widely used generic tool and was derived
from the larger 116-item measures of quality of life core survey.
It consists of 36 questions, split into eight domains with two
summary scores: the physical component summary (PCS) and
the mental component summary (MCS), as illustrated in Fig. 1.
In the most recent version, SF-36v2, all scores are expressed
as T-scores, normalised to the 2009 data from the general U.S.
population, with a score of 50 corresponding to the U.S. mean
and 1 standard deviation equal to 10. Preference-based health
utilities can be calculated using the SF-6D algorithm [15], which
uses 11 items across all domains other than general health to
generate a utility score on a 0.0–1.0 scale [16]. The sickness
impact proﬁle (SIP) has 136 questions, which make up 12 scales
in three dimensions. Higher scores represent greater impair-
ment and all 12 scales are summarised by an overall SIP score
on a 0–100 scale [17]. Another commonly used generic measure
is the Nottingham health proﬁle (NHP), which consists of two
parts: part one comprises 38 yes/no questions in six ‘‘subareas’’,
each of which is scored on a 0–100 scale, with higher scores
indicating poorer health status; part two assesses which of
seven areas of a patient’s life are affected by health problems
[18,19].
In addition to these generic tools, disease-speciﬁc measures
have been developed, which aim to measure more accurately
the speciﬁc impacts of liver disease on HRQOL. The most widely
used liver disease-speciﬁc measure is the chronic liver disease
questionnaire (CLDQ), which comprises 29 questions split into
six domains. Domain scores and an overall score are presented
on a 1–7 scale with higher scores representing better HRQOL
[20]. The liver disease quality of life (LDQOL) measure uses SF-
36v2 as a generic core and adds 12 liver-speciﬁc scales compris-
ing 75 questions. All scales are scored on a 0–100 scale with
higher values representing better HRQOL [21]. A short form ver-
sion, SF-LDQOL, has also been developed with 36 liver-speciﬁc
questions split into nine scales [22]. Finally, the liver diseasevol. 61 j 1158–1165 1159
Table 1. Generic HRQOL tools used in chronic liver disease.
Tool Format Structure Scoring Pros Cons
SF-36 36 Likert items 2 summary scores: Physical 
Component Summary and Mental 
Component Summary
8 domain scores: Physical 
Functioning, Role Physical, Bodily 
Pain, General Health,  Vitality, 
Social Functioning, Role Emotional, 
Mental Health
• All domains and summary 
scores expressed as T 
scores where 50 equal 
to mean US normative 
scores and 10 equal to 
one standard deviation.
• Higher scores correspond 
to better HRQOL
• Most widely used generic 
measure
• Multiple foreign language 
versions
• Allows comparison with 
other diseases
• Utility scores can be 
derived using SF-6D
• Norm based scoring.
• Shorter forms available 
(SF-8 and SF-12)
• License fee payable to 
use scoring algorithms
• US norms used 
which may differ from 
normative data from other 
populations
SIP 136 dichotomous 
items
12 domains in 3 dimensions: 1. 
Independent categories: sleep 
and rest, eating, work, home 
management, recreation and 
pastimes. 2. Physical dimension: 
ambulation, mobility, body care 
and movement. 3. Psychosocial 
dimension: social interaction, 
alertness behaviour, emotional 
behaviour, communication
1 overall score (0-100 scale)
• All domains and overall 
score expressed on 0-100 
scale. Higher scores 
correspond to greater 
impairment of HRQOL
• Widely used
• Allows comparison with 
other diseases
• Can be burdensome for 
respondents
• License fee payable to 
use
• No authorised foreign 
language translations
NHP 45 dichotomous 
items
6 domain scores: energy level, pain, 
emotional reaction, sleep, social 
isolation, physical abilities
7 life areas affected: occupation, 
jobs in the home, home life, social 
life, sex life, hobbies, holidays 
• Domain scores expressed 
on 0-100 scale. Higher 
scores correspond to 
greater impairment of 
HRQOL.
• Life areas affected: yes/
no response
• No license fee
• Quick to complete
• Validated foreign 
language versions
• Less widely used in 
liver disease than other 
generic tools
SF-36, short form-36; SIP, sickness impact proﬁle; NHP, Nottingham health proﬁle.
Reviewsymptom index 2.0 (LDSI) is made up of 18 items measuring the
severity and impact on daily activities in nine areas [23].Health related quality of life in cirrhosis
Before considering HRQOL in cirrhosis, it is useful to ﬁrst look at
the impact of the less advanced disease. Studies of chronic liver
disease have consistently shown that HRQOL is signiﬁcantly
poorer in both cirrhotic and non-cirrhotic patients than healthy
controls [24] or normative data [25]. Importantly, cirrhosis is
associated with poorer HRQOL than non-cirrhotic chronic liver
disease when measured by either CLDQ [25] or SF-36 [26]. Per-
haps unsurprisingly, studies comparing cirrhotic patients to the
general population have demonstrated signiﬁcantly impaired
HRQOL in cirrhosis [27,28] and a study comparing cirrhotic
patients with their carers showed that patients’ HRQOL scores
were signiﬁcantly poorer across a range of measures [29].
While impaired HRQOL might be expected, given the clinical
features of cirrhosis, it is helpful to characterise the extent and
nature of the impairment. Closer analysis of the factors underly-
ing poor HRQOL in cirrhosis should provide potential targets for
novel therapies and help detail outcome measures, which could
be used to assess future developments.Inﬂuence of liver disease severity on HRQOL
How does disease severity impact on the degree of HRQOL
impairment in chronic liver disease? In a cohort of 1103 chronic
liver disease patients, Child-Pugh score (CPS) class B or C cirrhosis
was associated with signiﬁcantly poorer SF-36 scores than class1160 Journal of Hepatology 2014A, but CPS classes B and C were similar [26]. This pattern has also
been demonstrated by other studies [28,30] while three studies
found signiﬁcant differences only in some domains and in the
PCS but not the MCS [20,31,32], although these were smaller
studies. One study found the CPS to be one of two variables which
correlated independently with the PCS [33]. The CPS was also
identiﬁed as an independent variable predictive of poor HRQOL
(>1SD worse than controls) in the PCS and 4 domains of the SF-
36 (PF, RP, VT, SF) as well as the energy and physical mobility
domains of the NHP [27].
Interestingly, one study showed that PCS deteriorated with
advancing CPS but multivariate analysis found that the CPS was
not an independent predictor of PCS [34]. However, all patients
included in this study had ascites; given that ascites is one of
the ﬁve parameters used to calculate the CPS, this observation
might suggest that ascites is the main driver of impaired HRQOL
seen with increasing CPS. Indeed, severe ascites was an indepen-
dent predictor of impaired PCS while serum bilirubin, albumin
and prothrombin time (PT), three of the four other CPS parame-
ters, were not [34].
CLDQ assessments of HRQOL show a similar pattern to SF-36
with respect to the CPS, with CLDQ scores of CPS class B and C cir-
rhosis signiﬁcantly worse than CPS class A, but the CLDQ did not
seem to discriminate between CPS class B and C [20,28,30].
An alternative disease-speciﬁc measure, the LDQOL, may bet-
ter differentiate between CPS classes. Two studies demonstrated
signiﬁcant associations between the CPS class and LDQOL in the
following domains: effects of liver disease, sexual functioning
and sexual problems [21,32], while the symptoms of liver disease
and stigma of liver disease domains were also signiﬁcantly asso-
ciated in the latter study [32]. In addition, the health utilities
index HUI-2 showed signiﬁcantly poorer utility scores withvol. 61 j 1158–1165
Table 2. Disease speciﬁc HRQOL tools used in advanced liver disease.
Tool Format Structure Scoring Pros Cons
CLDQ 29 Likert items 6 domain scores: abdominal 
12 liver specific domains:
symptoms, fatigue, systemic 
symptoms, activity, emotional 
function, worry 
1 overall score
• Domain and overall 
scores expressed on 
1-7 scale. Higher scores 
correspond to better 
HRQOL
• Simple scoring • May not be sensitive 
enough to capture small 
variations in HRQOL
LDQOL 75 Likert items 
+ SF-36 items symptoms, effects on activities of 
daily living, concentration, memory, 
sexual function, sexual problems, 
sleep, loneliness, hopelessness, 
quality of social interaction, health 
distress and self-perceived stigma 
of liver disease
• All domains scored on 
0-100 scale. Higher 
scores correspond to 
better HRQOL   
• May be more sensitive 
than CLDQ
• Limited published data 
using English version
SF-
LDQOL
36 Likert items 
+ SF-36 items
9 domains: symptoms, effects 
of liver disease, memory/
concentration, sleep, hopelessness, 
distress, loneliness, stigma of liver 
disease and sexual problems
1 overall score 
• All domains scored on 
0-100 scale. Higher 
scores correspond to 
better HRQOL
• May be more sensitive 
than CLDQ (e.g. responds 
to MELD)
• Limited published data
LDSI 18 Likert items 9 symptom severity items: itch, 
joint pain, abdominal pain, daytime 
sleepiness, worry about family 
situation, decreased appetite, 
depression, fear of complications, 
jaundice. 
9 symptom hinderance items
• Symptom severity items 
measured on 1-5 scale. 
Higher scores correspond 
to greater severity of 
symptoms. Symptom 
hinderence items 
measured on 0-10 scale. 
Higher scores correspond 
to greater impact on daily 
activities
• Limited published data
• Only validated in 
Netherlands
CLDQ, chronic liver disease questionnaire; LDQOL, liver disease quality of life; SF-LDQOL, short form liver disease quality of life; LDSI, liver disease symptom index.
JOURNAL OF HEPATOLOGYincreasing severity (non-cirrhosis vs. CPS A vs. CPS B vs. CPS C)
with a marked difference between CPS B and C (0.71 ± 0.27 vs.
0.46 ± 0.22) [25].
Data on the relationship between the model for end stage liver
disease (MELD) score and HRQOL are limited, partly because
MELD was not widely used until 2002 [35]. In a Polish study of
87 cirrhotic patients, signiﬁcant correlations were found between
the MELD score and both summary scores and ﬁve domains of SF-
36 [36]. Kanwal et al. found a signiﬁcant correlation between the
PCS and MELD score, but only 8% of patients had MELD scores >20
and the correlation was weaker than that seen with the CPS [32].
One study reported signiﬁcant differences between MELD 615
and >15 in four domains of SF-36 (SF, RP, BP, and GH) with no
summary score data [37]. In a study of 150 patients awaiting liver
transplantation, there was a weak correlation between both SF-
36 and CLDQ scores and MELD but univariate analysis showed
that MELD was not a predictor of either score [38].
There is evidence that LDQOL responds to theMELD score with
signiﬁcant associations seen with the effect of liver disease, health
distress, stigma of liver disease and sexual function domains [32].
In addition, the Brazilian-Portuguese translation of LDQOL reﬂects
differences in HRQOL when comparing MELD scores less than or
equal to 15 with scores greater than 15 [37,39].Inﬂuence of liver disease aetiology on HRQOL
A large number of studies have looked at how HRQOL differs
between liver diseases. A German study of non-cirrhotic patients
showed interesting differences in the pattern of impairment as
measured by SF-36, with PBC patients scoring lowest on the PCSJournal of Hepatology 2014while patients with HCV had the lowest MCS scores [40]. These
ﬁndings are consistent with other work which found fatigue to
be a key factor in PBC [41], while HCV has been shown to be asso-
ciated with depression [42]. By contrast, Younossi et al. showed
that in cirrhosis PCS was similar between cholestatic diseases
and viral hepatitis but poorer with other hepatocellular diseases
[30]. Another US study compared NAFLD, chronic HBV and HCV,
showing that NAFLD patients had signiﬁcantly poorer CLDQ
scores than patients with HBV in ﬁve of the six domains and in
the overall score. HCV scores were better than NAFLD in two
domains (emotional and systemic symptoms) but worse than
HBV in two domains (abdominal symptoms and activity). A far
greater proportion of patients with HCV had cirrhosis but in mul-
tivariate analysis the greater impairment in HRQOL seen with
NAFLD persisted after correction for cirrhosis as well as other fac-
tors such as diabetes, obesity and gender [43]. The same authors
also showed health utility scores SF-6D and HUI-2 to be signiﬁ-
cantly poorer with HCV than HBV in multivariate analysis [44].
A study which compared patients with cirrhosis of various causes,
also found that HRQOL was most impaired in HCV, with poorer
scores in seven of the twelve LDQOL domains and two of the eight
SF-36 domains [37]. However, data for other aetiologies were not
considered separately but instead combined into one ‘‘non-HCV
cirrhosis’’ category, likely due to small numbers. A larger study,
which included 761 cirrhotic patients, found that patients with
NAFLD had signiﬁcantly lower SF-36 PCS and PF than patients
with ALD, cholestatic liver disease or viral hepatitis [26]. On the
other hand, two studies found no difference in HRQOL between
aetiologies [31,33].
Therefore, the evidence of the impact of liver disease aetiology
on HRQOL is conﬂicting and there is no consistent pattern whichvol. 61 j 1158–1165 1161
  
  
       MCSPF RP BP GH VT SF RE MH PCS 
Fig. 1. SF36 structure. Summary scores (black): PCS, physical component
summary; MCS, mental component summary; Domains (white): PF, physical
function; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF,
social function; RE, role emotional; MH, mental health. All domains contribute to
both summary scores with domains ordered left to right from the domain which
contributes most to PCS (PF) to the domain which contributes most to MCS (MH).
Reviewwill be partly due to the heterogeneity in study design. However,
there is evidence that HRQOL is impaired in all aetiologies but the
pattern of impairment may vary between different aetiologies.
Chronic HBV infection appears to be associated with better
HRQOL than other aetiologies, while HCV and NAFLD are associ-
ated with poorer HRQOL.Inﬂuence of hepatic decompensation on HRQOL
While clinical experience of treating patients with advanced liver
disease suggests that patients with decompensated disease have
poorer HRQOL, it is useful to explore the speciﬁc ways in which
patients are affected by decompensation. A study from the US
found that the total SIP score was worse in decompensated cir-
rhosis than in compensated cirrhosis, as were several domains
of the SIP. A computerised tool, PROMIS-CAT, was also used,
which showed greatest impairment in social functioning, physi-
cal functioning and pain domains [29]. A Dutch study also
showed that patients with decompensated cirrhosis had poorer
HRQOL using SF-36, the multidimensional fatigue index-20
(MFI-20) and LDSI. Interestingly, the authors describe a subgroup
of patients as ‘‘reversed decompensated cirrhotic patients’’ who
had a previous episode of decompensation, but who were com-
pensated at the time of the study, for example following treat-
ment of ascites with diuretics. The HRQOL of these patients was
comparable to patients with compensated cirrhosis and hence
they were classiﬁed as compensated cirrhosis [45]. This suggests
that resolution of decompensation is associated with an improve-
ment in HRQOL to levels seen in compensated disease, implying
that there is potential to vastly improve patient HRQOL through
effective treatment of decompensation. This perhaps ‘‘raises the
bar’’ in decompensated disease, particularly in the management
of ascites or hepatic encephalopathy (HE), giving rise to the con-
cept that a structured approach could be taken to improving
HRQOL in advanced liver disease through the speciﬁc targeting
of individual complications such as ascites and encephalopathy.Inﬂuence of ascites on HRQOL
In a study of 544 patients with cirrhosis including 199 patients
with ascites, Marchesini et al. showed signiﬁcant differences in
most SF-36 and NHP domains when comparing patients without
ascites to those with either mild-to-moderate or severe ascites.
Ascites was found to be an independent predictor of poor HRQOL
in three SF-36 domains (bodily pain, general health and mental
health) but of neither summary score nor any of the NHP
domains [27]. On the other hand, in a study of 523 patients, all1162 Journal of Hepatology 2014of whom had ascites, the presence of severe (tense) ascites was
found to be an independent factor predictive of impaired PCS in
multivariate analysis [34]. In a study of 160 cirrhotic patients,
the 69% with a history of ascites had signiﬁcantly poorer SF-36
PCS, but MCS was similar to those without ascites [31]. This
was conﬁrmed by a Swedish study, which also assessed GI symp-
toms using the GI symptoms rating scale. Signiﬁcantly more
severe GI symptoms were seen with ascites in the following
domains: abdominal pain, indigestion, constipation and eating
dysfunction [46].
Therefore, ascites appears to affect HRQOL predominantly
through physical impairment, driven at least partly by GI symp-
toms, although one study did report signiﬁcant impairment of
the SF-36 MCS as well as the PCS [47]. Ascites also associates with
patients’ self-rating of disease progression over the preceding
year [27], suggesting that the development of ascites signals to
patients a deterioration in their condition, potentially further
impacting HRQOL.
Treatment of refractory ascites with transjugular intrahepatic
portosystemic shunt (TIPS) insertion might be expected to lead
to considerable gains in HRQOL, for example through reduced
abdominal symptoms, fewer hospital admissions and improved
body image. However, on one hand a randomised controlled trial
(RCT) found that HRQOL was similar in both the TIPS and control
groups, due to the development of post TIPS HE in some patients,
offsetting the improvements due to reduced ascites [48]. On the
other hand, meta-analyses have reported a survival beneﬁt
[49,50], suggesting that additional multi-centre studies of TIPS in
refractory ascites, including HRQOL assessment, would be useful.Inﬂuence of hepatic encephalopathy (HE) on HRQOL
One small study compared 18 patients with previous overt HE
(OHE) with 57 patients without a previous episode. Patients with
previous OHE had signiﬁcantly worse SF-36 PCS and MCS and this
variable was found to be an independent predictor of the MCS.
However, the presence of minimal HE (MHE) affected only one
domain of SF-36 (physical functioning); PCS and MCS were unaf-
fected [47]. Similar ﬁndings were reported by another study,
which assessed the impact of MHE on HRQOL in 77 cirrhotic
patients without a history of OHE. No signiﬁcant differences were
found in any of the CLDQ or SF-36 domains or summary scores
when comparing patients with MHE to those without [36].
By contrast, a study of 160 patients with cirrhosis undergoing
assessment for liver transplantation showed that patients with
either MHE or OHE had lower MCS scores than patients without
HE. Interestingly, the presence of OHE most greatly affected the
PCS [31]. Another study of 106 patients with cirrhosis, excluded
patients with previous OHE and showed patients with MHE had
signiﬁcantly poorer scores in all SF-36 domains than those with-
out MHE. However, CLDQ scores were similar between these two
groups, with the exception of the abdominal symptoms domain
[28]. Baseline data from an RCT of lactulose for MHE showed that
patients with MHE had signiﬁcantly poorer SIP scores in all but
one domain. Treatment with lactulose improved total SIP scores,
which correlated with improved psychometric test performance.
In addition, in multivariate regression analysis, MHE was the only
variable found to be signiﬁcantly related to HRQOL (CPS, varices,
aetiology and education status were the other variables tested)
[51], consistent with an earlier study [52]. In an RCT of rifaximinvol. 61 j 1158–1165
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in MHE, baseline data showed that patients with MHE had signif-
icantly impaired HRQOL across all 12 scales and in the overall
score of the SIP. In addition, treatment with rifaximin improved
both SIP scores and psychometric tests for MHE [53]. Another
RCT of rifaximin evaluated its use in the maintenance of remis-
sion following an episode of OHE. All CLDQ domains were signif-
icantly poorer in patients with a breakthrough episode of OHE
compared with patients remaining in remission [54].Inﬂuence of other factors on HRQOL
Other clinical factors which have been shown to impact HRQOL
include the presence of comorbidities, with one study of HCV
patients showing increasing impairment of health utilities and
SF-36 summary scores with increasing levels of comorbidity, as
measured by either the Charlson score or the index of coexistent
disease [55]. The number of different medications taken daily,
which reﬂects the comorbidity burden, has also been demon-
strated to be signiﬁcantly associated with most domains of SF-
36 and NHP [27]. Prescription of speciﬁc medications has also
been studied; loop diuretics have been shown to be associated
with impairment of most SF-36 domains [27], while in another
study, diuretic and beta-blocker use were found to be the only
two variables predictive of PCS in multivariate regression analy-
sis, although their effects were limited to patients with decom-
pensated cirrhosis [56]. A diagnosis of type 2 diabetes was
associated with impaired MCS and PCS in a study of patients with
NAFLD, while a BMI of >40 kg/m2 affected the PCS [57]. In their
study of patients with ascites, Sola et al. showed that hyponatra-
emia was an important contributor to impaired HRQOL with
serum sodium identiﬁed as an independent predictive factor of
both PCS and MCS in multivariate analysis [34]. The development
of HCC has also been shown to adversely affect HRQOL. One study
compared HCC patients to chronic liver disease controls, matched
by age, sex, aetiology and disease severity, showing that HCC was
associated with poorer HRQOL, affecting predominantly physical
aspects of the NHP and SF-36 [58]. The need for detailed assess-
ment of HRQOL in HCC has resulted in the development of HCC-
speciﬁc measures as well as the use of generic cancer measures,
which are reviewed elsewhere [59]. Interestingly, there is evi-
dence that better HRQOL at baseline is associated with longer
survival in HCC [60].
Non-clinical factors have also been considered with respect to
HRQOL in advanced liver disease. One study which converted SF-
36 and NHP to Z-scores compared with age- and sex-matched
healthy controls showed that younger patients had greater
impairment in HRQOL, most likely due to better HRQOL scores
in younger controls relative to older controls [27]. Conversely,
one study of 713 patients with NAFLD found that increasing
age was signiﬁcantly associated with poorer PCS, but not MCS,
in univariate and multivariate analysis, however only 9.3% of this
cohort were cirrhotic [57]. A correlation between increasing age
and worsening SF-36 scores has been reported in another study
of 1103 chronic liver disease patients (69% cirrhosis) [26]. These
two studies also found in multivariate regression analysis that
female patients had signiﬁcantly poorer MCS and PCS scores
[26,57]. Two studies showed that liver patients with lower
income have signiﬁcantly impaired PCS and MCS [55,57], while
another showed an effect on two domains (Physical Functioning
and Mental Health) [61]. In addition, this study showed thatJournal of Hepatology 2014higher education level was associated with better mental health
scores, while another showed NAFLD patients who did not attain
a high school diploma had signiﬁcantly poorer MCS than those
who were better educated [57]. Patients who are married or liv-
ing with a partner have been shown to have better HRQOL than
those who are divorced, separated or widowed [55,57,62].Conclusions
It is clear that advanced chronic liver disease is associated with
dramatically impaired HRQOL. The literature provides key evi-
dence to support a multifactorial model of HRQOL impairment
in advanced liver disease. For example, we know that some of
the clinical factors, which worsen HRQOL, include disease sever-
ity, the presence of ascites or encephalopathy and hyponatra-
emia. It is therefore unlikely that a single global intervention
will improve HRQOL in advanced liver disease, but rather by sys-
tematically focusing on the individual contributing factors with a
reversal component, overall improvements may be possible.
Indeed there is some evidence to support improved HRQOL
through effective treatment and improvement or resolution of
decompensation. There is a signiﬁcant need, however, to explore
the responsiveness of HRQOL to systematic intervention to
improve reversible manifestations of advanced liver disease such
as ascites and encephalopathy in properly designed longitudinal
studies using appropriate HRQOL outcome measures.
Modern healthcare places a great importance on demonstrat-
ing cost-effectiveness of new treatments. The methodology used
in such technology appraisals is critically important as it affects
whether or not a new treatment will be made available to
patients, as exempliﬁed by recent assessments of sorafenib for
HCC [63]. QALYs vary greatly depending on the technique used
for the derivation of health utility scores, as demonstrated with
chronic HCV [64]. Many advocate the use of patient-derived util-
ity scores, for which a robust measure of HRQOL is essential.
There is also a drive to provide care, which is more patient-cen-
tric, with a focus on the issues which matter most to patients and
their carers; hence, a greater emphasis on HRQOL, in both clinical
practice and research, is required.
Many treatments for advanced liver disease aim to be life-
enhancing, rather than life-prolonging. Evaluation of future ther-
apies should therefore include HRQOL assessment, with tools
chosen to provide sensitivity to changes relevant to the clinical
setting. We recommend the use of a robust generic measure, such
as SF-36 or SIP, in combination with a disease speciﬁc measure.
While there are more studies published using the CLDQ, serious
consideration should be given to the use of the LDQOL, or the
short-form version SF-LDQOL, as an alternative liver disease-spe-
ciﬁc measure in studies of cirrhosis, as these seem to provide
greater responsiveness to changes seen in more advanced dis-
ease. Finally, consideration should be given to the way in which
care delivery contributes; HRQOL driven service evaluation and
improvement will likely bring further gains.Financial support
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